Jessica Y. Schneider

Koeln, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Journal: Blood advances
Published: December 05, 2025

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma.

Journal: Blood advances
Published: December 05, 2025

Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Rapid molecular response kinetics to anti-PD-1-based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Journal: Blood advances
Published: October 10, 2025

Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Rapid molecular response kinetics to anti-PD1 based first-line treatment of Hodgkin lymphoma in the GHSG NIVAHL trial.

Journal: Blood advances
Published: October 10, 2025

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

Journal: Blood
Published: September 15, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances
Published: September 15, 2025

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.

Journal: Blood advances
Published: September 15, 2025

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay.

Journal: Blood
Published: September 15, 2025

PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma.

PFS24 as a prognostic milestone in patients with newly diagnosed primary CNS lymphoma.

Journal: Journal of hematology & oncology
Published: February 10, 2025

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 30, 2024

Linking Functional Traits To Trophic Roles In Scavenger Assemblages.

Linking Functional Traits To Trophic Roles In Scavenger Assemblages.

Journal: Ecology and evolution
Published: May 23, 2024

Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.

Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.

Journal: European journal of haematology
Published: November 06, 2023
Showing 1-12 of 38

Last Updated: 09/26/2026